Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 32s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Lactobacillus as Anti-Biofilm Therapeutics: Formulation and Delivery Challenges in Clinical Translation

Bharathi B.V.N.V[1]*, Anila Rani Pullagura[2], Prem Kumar Essgir[3], R. Bharathnaik[4], Muni Kumar Dokka[5]

[*1]Assistant Professor & HOD, Department of Life Sciences, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.

[2]Associate Professor, Department of Life Sciences, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.

[3]Assistant Professor, Department of MLT, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.

[4]Assistant Professor, Department of Life Sciences, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.

[5]Associate Professor, Department of Biochemistry, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.

***Corresponding author:**

Bharathi B.V.N.V

Email ID: bharathi.b@mallareddyuniversity.ac.in

Cite this paper as: Bharathi B.V.N.V, Anila Rani Pullagura, Prem Kumar Essgir, R. Bharathnaik, Muni Kumar Dokka, (2025) Lactobacillus as Anti-Biofilm Therapeutics: Formulation and Delivery Challenges in Clinical Translation. *Journal of Neonatal Surgery*, 14 (32s), 4956-4966.

ABSTRACT

Background: Biofilm-associated infections contribute to nearly 65% of all microbial infections and are notoriously resistant to conventional antibiotics. The protective extracellular polymeric matrix and metabolic heterogeneity of biofilms make treatment particularly challenging. *Lactobacillus* species have emerged as promising anti-biofilm agents due to their ability to produce antimicrobial compounds, disrupt biofilm architecture, and enhance host immune responses. However, their clinical application remains limited by significant formulation and delivery barriers. The objective of the review is to critically evaluate the anti-biofilm potential of *Lactobacillus*, identify the key challenges hindering its clinical translation, and explore technological and regulatory strategies to overcome these limitations.

Methods: This review integrates current literature on the antimicrobial mechanisms of *Lactobacillus*, assesses the environmental and physiological stressors impacting therapeutic viability, and analyzes recent advances in protective formulation technologies, genetic engineering, and synergistic therapies. The review also examines the regulatory landscape governing Live Biotherapeutic Products (LBPs).

Results: *Lactobacillus* exerts multi-modal anti-biofilm effects through the production of organic acids, bacteriocins, biosurfactants, and hydrogen peroxide, alongside competitive exclusion and immunomodulation. However, survival is severely compromised by manufacturing stress, gastric acidity, bile exposure, oxidative damage, and microbiota competition. Technological innovations such as microencapsulation, enteric coatings, biofilm-based delivery platforms, and CRISPR-based strain enhancements significantly improve viability and efficacy. Combination therapies with bacteriophages and matrix-degrading enzymes offer synergistic benefits. Nonetheless, the regulatory framework for LBPs demands extensive characterization, safety assurance, and novel clinical trial designs, presenting additional hurdles.

Conclusion: *Lactobacillus*-based therapeutics offer a promising solution for biofilm-related infections, but successful clinical translation demands integrated advances in formulation, genetic engineering, regulation, and personalized strategies—driven by interdisciplinary collaboration

Keywords: *Lactobacillus; biofilm; antimicrobial resistance; live biotherapeutic products; encapsulation; CRISPR; probiotic delivery; regulatory challenges; microbial therapeutics.*

1. INTRODUCTION

The emergence of biofilm-associated infections has fundamentally transformed our understanding of microbial pathogenesis and therapeutic resistance. These sophisticated bacterial communities, protected by self-produced extracellular polymeric matrices, exhibit resistance levels up to 1,000 times greater than those of individual planktonic bacteria [1]. This extraordinary resilience emerges through coordinated defence mechanisms, including protective matrices that block drug penetration, metabolic diversity within biofilms that create subpopulations with varying antimicrobial susceptibilities and accelerated horizontal gene transfer that rapidly disseminates resistance traits [2].

Healthcare systems worldwide now confront an escalating crisis driven by biofilm-mediated infections. Device-associated infections, chronic wounds resistant to healing, and persistent respiratory infections exemplify clinical scenarios where biofilm formation drives treatment failure and patient morbidity. Traditional antibiotics, designed primarily for planktonic bacteria, consistently prove inadequate against these organized microbial communities, creating an urgent demand for innovative therapeutic strategies [3].

Lactobacillus bacteria present a compelling alternative approach to biofilm-associated infections. These microorganisms, which humans have safely consumed for millennia in fermented foods, possess natural anti-biofilm properties that extend far beyond simple antimicrobial activity. They excel at the competitive displacement of pathogens, actively disrupt biofilm architectures, and enhance immune system function [4]. However, despite extensive research documenting these beneficial properties, few *Lactobacillus*-based therapies have successfully transitioned to clinical application.

This translational gap primarily stems from the unique challenges inherent in developing living therapeutics. Unlike chemical drugs that remain stable under diverse conditions, bacterial treatments must overcome environmental stresses, navigate complex physiological barriers, and establish themselves within existing microbial ecosystems. This review systematically examines the primary obstacles preventing clinical translation, analyzes emerging technological solutions, and provides strategic recommendations for advancing these promising therapeutics, from laboratory discoveries to patient care.

2. THE MULTI-FACETED ANTI-BIOFILM ARSENAL OF *LACTOBACILLUS*

2.1 Chemical Warfare: Diverse Antimicrobial Mechanisms

Lactobacillus bacteria deploy an impressive array of chemical weapons against pathogenic biofilms. Their strategy operates through multiple complementary mechanisms that function both independently and synergistically to create hostile microenvironments for pathogenic organisms (Table 1).

Table 1: *Lactobacillus* Anti-Biofilm Compounds: Properties and Therapeutic Applications

Bioactive Compound	Producer Strains	Mechanism of Action	Target Spectrum	Therapeutic Concentration	Stability Profile
Lactic Acid	*L. acidophilus*, *L. plantarum*	Environmental acidification, membrane disruption	Gram-positive bacteria, select Gram-negative	0.5-2.0% w/v	High stability (heat/pH resistant)
Nisin (Class I Bacteriocin)	*L. lactis* subsp. *Lactis*	Pore formation in cell membranes	Gram-positive pathogenic bacteria	25-100 μg/mL	Moderate stability (heat labile)
Hydrogen Peroxide	*L. acidophilus*, *L. johnsonii*	Oxidative damage to cellular components	Broad-spectrum antimicrobial	0.1-0.5 mM	Low stability (rapidly degraded)
Phenyllactic Acid	*L. plantarum*, *L. brevis*	Membrane permeabilization	Fungi, Gram-positive bacteria	2-8 mM	High stability (chemically robust)
Biosurfactants	*L. casei*, *L. fermentum*	Surface tension reduction, biofilm dispersal	Broad-spectrum biofilm disruption	50-200 μg/mL	Variable stability (structure dependent)

Bioactive compounds produced by *Lactobacillus* species with demonstrated anti-biofilm activity

*Producer strains represent well-characterized species known for their ability to produce compounds.

*Mechanism of action describes the primary mode of antimicrobial or anti-biofilm activity.

*Target spectrum indicates the range of susceptible microorganisms.

*Therapeutic concentrations are effective ranges observed in laboratory studies.

*Stability profiles indicate the durability of compounds under typical storage and physiological conditios, which directly impact clinical utility and formulation requirements.

Organic Acid Production: Lactic acid, the primary metabolic end-product, serves as the fundamental weapon system. This compound creates highly acidic microenvironments (pH 3.5-4.5) that selectively eliminate acid-sensitive pathogens while remaining compatible with human tissues. The targeted acidification disrupts pathogen metabolism and compromises cell wall integrity, effectively creating hostile territories for harmful bacteria while preserving beneficial microorganisms [5].

Bacteriocin-Mediated Targeting: Many *Lactobacillus* strains produce sophisticated protein antibiotics called bacteriocins. These molecules demonstrate remarkable target specificity, with Class II bacteriocins showing particularly broad-spectrum activity against Gram-positive pathogens while maintaining stability across diverse physiological conditions. Unlike broad-spectrum chemical antibiotics, bacteriocins often target specific bacterial species or strains, thereby reducing the disruption of beneficial microbial communities [6].

Oxidative Stress Induction: The production of hydrogen peroxide introduces an oxidative dimension to the antimicrobial strategy. This reactive molecule damages pathogen proteins, genetic material, and cellular membranes; however, its effectiveness varies significantly among different *Lactobacillus* strains, depending on their metabolic capabilities. This oxidative stress selectively affects bacteria that lack robust antioxidant defence systems, often sparing host cells and beneficial microbes.

2.2 Competitive Strategies and Physical Disruption

Beyond direct antimicrobial activity, *Lactobacillus* excels at resource competition and territorial control. These bacteria rapidly consume nutrients essential for pathogen growth while simultaneously occupying prime adhesion sites on host surfaces. This competitive exclusion proves most effective when beneficial bacteria establish themselves before pathogenic colonization occurs, highlighting the importance of preventive therapeutic applications [7].

Several strains demonstrate active biofilm-disrupting capabilities through co-aggregation mechanisms. By physically binding to harmful bacteria, *Lactobacillus* cells facilitate the removal of pathogens from infection sites. This "cellular adhesion" effect not only prevents initial biofilm formation but can also extract established pathogens from existing communities.

Certain strains actively dismantle existing biofilm structures through enzymatic mechanisms. They produce specialized enzymes that degrade protective matrices while secreting biosurfactants, which alter the surface chemistry of the surrounding environment. These coordinated attacks weaken biofilm architecture and promote dispersal, making embedded pathogens significantly more accessible to therapeutic interventions [8].

2.3 Communication Disruption and Immune Enhancement

Lactobacillus bacteria interfere with bacterial communication networks by disrupting sophisticated quorum-sensing mechanisms. They systematically degrade chemical signalling molecules or produce competitive inhibitors that prevent the coordinated development of biofilms. This communication interference effectively prevents the synchronized production of virulence factors, rendering pathogenic communities more susceptible to immune attacks and antimicrobial treatments.

Simultaneously, these bacteria forge productive partnerships with the human immune system. They strengthen epithelial barriers, promote beneficial inflammatory responses, and actively support natural mechanisms for pathogen clearance. This immunomodulatory capacity extends the therapeutic potential well beyond direct antimicrobial effects, creating conditions that favour the long-term resolution of infection [9].

Lactobacillus bacteria function as sophisticated biological weapons employing four complementary mechanisms: chemical warfare through acids and bacteriocins, competitive displacement and physical disruption, communication interference, and immune system enhancement. This multimodal approach addresses biofilm complexity more comprehensively than single-target therapies; however, harnessing this potential requires overcoming significant formulation and delivery challenges.

3. THE FORMULATION CHALLENGE: NAVIGATING ENVIRONMENTAL HOSTILITY

3.1 Environmental Stress Cascade

Despite their therapeutic promise, living treatments face environmental challenges that chemical pharmaceuticals often overcome more easily. These biological vulnerabilities create a formulation crisis that systematically eliminates therapeutic populations before clinical benefit can occur (Table 2).

Temperature Sensitivity: Even brief exposure to temperatures above 60°C during manufacturing processes can cause catastrophic bacterial death, eliminating more than 99.9999% of the population within five minutes through protein denaturation and cell wall destruction. This extreme sensitivity severely limits processing options and necessitates the use of expensive cold-chain storage throughout the product's lifecycle.

Gastric Acid Barrier: Exposure to stomach acid creates a nearly insurmountable obstacle for orally administered treatments. The harsh acidic environment (pH 1.0-2.5) eliminates 90-99% of bacterial populations during typical gastric transit, leaving insufficient survivors to establish therapeutic populations at target sites. This physiological barrier particularly affects treatments for systemic or lower gastrointestinal infections.

Oxidative Damage: Exposure to atmospheric oxygen progressively damages bacteria that lack protective antioxidant systems. Many *Lactobacillus* strains evolved in low-oxygen environments and consequently lack enzymes such as catalase and superoxide dismutase, which are necessary for aerobic survival. This vulnerability compounds during the manufacturing, storage, and administration phases [10].

Osmotic Stress: Dehydration processes essential for product stability create an osmotic shock that damages cell walls and compromises bacterial function. These cumulative stresses create a cascade where each processing step further reduces viable bacterial populations available for therapeutic action.

Table 2: Environmental and Physiological Barriers to *Lactobacillus* Therapeutic Delivery

Barrier Type	Stress Condition	Bacterial Survival Rate	Critical Control Strategy	Therapeutic Consequence
Manufacturing Stress	Heat exposure >60°C	<0.0001% survive	Cold-chain processing, lyophilization	Product viability loss
Gastric Transit	pH 1.0-2.5 for 2 hours	1-10% survive	Enteric coating, timing with meals	Subtherapeutic dosing
Intestinal Environment	Bile salts 2-20 mM	5-30% survive	Strain selection, protective matrices	Variable efficacy
Oxidative Exposure	Atmospheric oxygen	10-50% survive	Anaerobic packaging, antioxidants	Reduced shelf stability
Microbiome Interference	Indigenous bacterial competition	0-90% establish	Personalized dosing, pretreatment	Unpredictable outcomes

*Sequential barriers encountered by *Lactobacillus* therapeutics from manufacturing through clinical delivery.

*Survival rates represent typical ranges observed across different strains and formulations.

*Critical control strategies indicate proven approaches to mitigate each barrier

*Therapeutic consequences describe the clinical impact of uncontrolled losses at each stage

3.2 Manufacturing and Scale-Up Complexities

Transitioning from laboratory success to commercial production introduces complications absent in chemical drug manufacturing. Living systems exhibit inherent biological variability, which creates batch-to-batch differences that often exceed acceptable pharmaceutical standards. Critical fermentation parameters—including nutrient composition, pH control, dissolved oxygen levels, and temperature fluctuations—all significantly influence final product characteristics [11].

Quality control becomes exponentially more complex than for traditional pharmaceuticals. Manufacturers must simultaneously monitor bacterial viability, genetic stability, contamination levels, and functional activity—parameters for which standardized testing methods are still being developed. This biological complexity directly impacts both regulatory approval timelines and commercial viability assessments.

Scaling production from laboratory flasks to industrial bioreactors frequently alters bacterial characteristics in unpredictable ways. Hydrodynamic stresses, altered nutrient gradients, and different oxygen transfer rates can all modify cellular properties, potentially compromising therapeutic efficacy [12].

3.3 Protective Technology Solutions

Recent technological advances offer promising solutions to these long-standing problems. Smart encapsulation systems now provide sophisticated, multi-layered protection using materials that respond to specific environmental triggers (Table 3).

These innovations enable precise control over bacterial release timing and location, resulting in significant improvements in delivery success rates compared to unprotected formulations.

Enteric coating technologies protect bacteria from stomach acid while ensuring their release in the more hospitable environment of the small intestine. This targeted approach can enhance bacterial survival by 100 to 1000 times over unprotected formulations, ultimately making oral delivery viable for many therapeutic applications.

The formulation challenge represents a cascade of environmental hostilities that systematically eliminate bacterial populations from manufacturing through clinical delivery. Temperature stress, gastric acid exposure, and oxidative damage create successive barriers to therapeutic success. However, emerging protective technologies—such as brilliant encapsulation and enteric coating systems—offer viable pathways to overcome these obstacles and transform laboratory potential into clinically deliverable therapeutics.

4. DELIVERY CHALLENGES: THE JOURNEY TO THERAPEUTIC EFFICACY

4.1 Physiological Barrier Navigation

The path from formulation to therapeutic action involves multiple interconnected challenges that compound throughout the delivery process. Each barrier systematically reduces bacterial populations, often to levels below therapeutic thresholds, before reaching target sites (Figure 1).

Sequential Gastrointestinal Obstacles: Oral delivery, the preferred route for most *Lactobacillus* therapies, encounters severe sequential barriers. Antimicrobial enzymes in saliva initiate bacterial elimination before they reach the stomach. Subsequently, stomach acid serves as the primary barrier, eliminating 90-99% of bacterial populations within minutes. Bile salts in the small intestine—acting as biological detergents—damage remaining cell walls and cause substantial additional losses.

Extended transit times through the gastrointestinal system increase the cumulative elimination of bacteria. Unlike chemical drugs that remain stable during absorption, living bacteria face continuous environmental assault throughout their journey, making delivery timing and protective strategies critically important for therapeutic success [13].

Table 3: Advanced *Lactobacillus* Formulation Technologies and Clinical Performance

Technology Platform	Protection Mechanism	Survival Enhancement	Development Complexity	Clinical Status
Alginate Microencapsulation	pH-responsive polymer matrix	100-1000× gastric protection	Moderate scalability	Phase II trials
Enteric Coating Systems	Acid-resistant film barrier	500-5000× acid tolerance	Low complexity	Commercial products
Biofilm-Matrix Delivery	Natural EPS protection	50-500× stress resistance	High manufacturing complexity	Research phase
Smart Hydrogel Carriers	Environment-triggered release	200-2000× targeted delivery	Very high complexity	Early development
Multi-Layer Encapsulation	Graduated barrier protection	1000-10000× combined resistance	Extremely high complexity	Proof-of-concept

Comparison of emerging formulation technologies for *Lactobacillus* therapeutic delivery

*Survival enhancement represents fold-improvement over unprotected bacteria under simulated gastrointestinal conditions.

*Development complexity reflects manufacturing scalability and regulatory requirements.

*Clinical status indicates current translational progress from research to commercial application.

Figure 1: The *Lactobacillus* Therapeutic Delivery Challenge Cascade



This comprehensive flowchart illustrates the sequential population losses that *Lactobacillus* therapeutics encounter from initial laboratory formulation (starting population:10^{10} bacteria/mL) through successful clinical delivery. The figure emphasizes that successful delivery requires coordinated protection strategies across the entire pathway rather than addressing individual barriers in isolation.

The cascade demonstrates five critical bottlenecks:

(A) Laboratory-to-Manufacturing Transition: Temperature stress (>60°C), pH fluctuations, and oxidative exposure during scale-up reduce populations by 3-4 log units. Quality control checkpoints and protective additives provide partial mitigation.

(B) Manufacturing and Storage: Dehydration processes, packaging stresses, and extended storage periods result in an additional 1-2 log reduction. Cold-chain maintenance and moisture control are essential for product stability.

(C) Administration and Gastric Transit: Oral delivery encounters severe pH stress (1.0-2.5) in the stomach, resulting in the elimination of 90-99% of the remaining bacteria. Enteric coating and timing strategies offer protection.

(D) Intestinal Survival: Exposure to bile salts (2-20 mM) and enzymatic degradation in the small intestine leads to further population losses. Strain selection and protective matrices enhance survival.

(E) Target Site Establishment: Competition with indigenous microbiota and biofilm penetration barriers determine final therapeutic colonization success. Patient-specific factors significantly influence outcomes.

Critical Decision Points: Pass/fail thresholds at each stage determine advancement to clinical efficacy. Intervention opportunities (protective technologies, timing optimization, personalized approaches) are highlighted throughout the cascade. The figure emphasizes that successful therapeutic delivery requires coordinated protection strategies across the entire pathway rather than addressing individual barriers in isolation.

Intervention Opportunities:

Stage A: Cold-chain processing, protective additives

Stage B: Anaerobic packaging, moisture control

Stage C: Enteric coating, meal timing

Stage D: Strain selection, protective matrices

Stage E: Personalized dosing, pretreatment

4.2 Target Site Access and Biofilm Penetration

Bacteria surviving gastrointestinal transit must overcome additional hurdles to reach infection sites. Established biofilms form complex three-dimensional architectures with restricted diffusion pathways, severely limiting therapeutic bacterial access to embedded pathogens. The same dense protective matrices that shield harmful bacteria from antibiotics also present formidable barriers to the penetration of beneficial bacteria.

This penetration challenge becomes particularly acute in mature biofilms, where nutrient gradients, oxygen limitations, and waste accumulation create microenvironments that may not support the growth or activity of *Lactobacillus*. Consequently, intervention timing becomes crucial—early treatment during biofilm formation proves far more effective than attempting to penetrate established communities [14].

4.3 Microbiome Ecological Complexity

The human microbiome presents a complex ecological system that actively resists colonization by external bacteria. Indigenous bacterial communities offer sophisticated colonization resistance mechanisms that limit the effectiveness of *Lactobacillus* treatments in establishing and persisting. This natural defence system, while protective against pathogens, unfortunately also restricts the colonization of beneficial bacteria.

Individual microbiome composition varies dramatically based on genetic factors, dietary patterns, age, health status, and medication history. This variation creates patient-specific barriers to the establishment of therapeutic bacteria, making treatment outcomes highly unpredictable. Established microbial communities actively compete for resources and binding sites, often outcompeting introduced *Lactobacillus* strains even when the latter possess superior anti-biofilm properties [15].

The delivery journey represents a multi-stage obstacle course where physiological barriers, biofilm architecture, and microbiome competition systematically reduce therapeutic bacterial populations. Success requires not only surviving the delivery journey but also establishing sustainable populations capable of therapeutic action. This reality highlights the crucial importance of protective technologies and personalized treatment strategies.

5. ENGINEERING SOLUTIONS: TECHNOLOGICAL INNOVATION AND INTEGRATION

5.1 Advanced Encapsulation Technologies

Modern microencapsulation technology has evolved beyond simple bacterial coating to create sophisticated, responsive delivery systems. Contemporary encapsulation strategies employ graduated protection where outer layers handle manufacturing and storage stresses while inner layers target specific physiological barriers. Alginate-chitosan systems provide initial protection during processing, while pH-responsive polymers ensure controlled release in the appropriate intestinal environment, achieving 100-to 1000-fold improvements in bacterial survival [16].

Smart materials that respond to environmental triggers enable unprecedented precision in delivery timing and location. These systems can sense pH changes, enzyme activity, or specific molecular signals to trigger bacterial release precisely when and where needed, thereby maximizing therapeutic effectiveness while minimizing off-target effects.

5.2 Biofilm-Based Delivery Strategies

An innovative approach harnesses biofilm formation as a therapeutic advantage rather than a manufacturing obstacle. *Lactobacillus* delivered in pre-formed biofilm communities demonstrates dramatically enhanced stress tolerance, improved host tissue adhesion, and increased resistance to environmental challenges compared to individual bacterial cells.

These biofilm-delivery systems create protective microenvironments that support long-term bacterial colonization and sustained therapeutic activity. Additionally, biofilm-based formulations offer unique opportunities for combination therapies where different bacterial strains within the same protective matrix provide complementary therapeutic functions, essentially creating "designer microbial communities" optimized for specific clinical applications [17].

5.3 Genetic Engineering and CRISPR Enhancement

CRISPR technology has revolutionized the ability to engineer *Lactobacillus* strains with enhanced therapeutic properties tailored for specific clinical applications. Targeted genetic modifications can systematically improve stress tolerance, dramatically increase antimicrobial compound production, or introduce entirely novel therapeutic functions not found in natural strains.

Researchers have successfully engineered strains with improved acid tolerance for better gastric survival, enhanced adhesion properties for superior colonization, and increased bacteriocin production for more potent antimicrobial effects. These designer probiotics represent the next generation of living therapeutics, optimized through precision engineering rather than random selection [18].

Safety considerations remain paramount in genetic engineering applications. Sophisticated containment strategies, including biological kill switches and growth dependencies, ensure that modified organisms cannot persist indefinitely in natural environments or transfer engineered traits to wild-type bacteria.

5.4 Synergistic Multimodal Approaches

Combination strategies represent perhaps the most promising approach for overcoming the limitations inherent in single-agent therapies. These multimodal treatments orchestrate complementary mechanisms to achieve synergistic therapeutic effects that are greater than the sum of their components (Figure 2).

Figure 2: Synergistic Multimodal Anti-Biofilm Therapy Against Pathogenic Biofilms



This schematic illustrates a coordinated therapeutic action where bacteriophage therapy creates initial clearance zones, enzymatic degradation expands accessible areas, and *Lactobacillus* colonization prevents pathogenic reestablishment. This temporal coordination addresses biofilm complexity through multiple simultaneous mechanisms, resulting in synergistic effects that exceed those of individual treatments.

This detailed schematic demonstrates the coordinated therapeutic action of three complementary treatment modalities against established pathogenic biofilms on medical device surfaces. The illustration progresses through three temporal phases:

(A) Initial Biofilm State (0 hours): Shows a mature pathogenic biofilm with characteristic features including: dense extracellular polymeric substance (EPS) matrix, embedded bacterial microcolonies, nutrient gradients from surface to bulk fluid, and protective barriers that exclude traditional antibiotics. The biofilm architecture demonstrates the three-dimensional complexity that makes these infections refractory to standard treatments.

(B) Coordinated Therapeutic Intervention (0-24 hours): Depicts the synchronized deployment of three therapeutic modalities:

- **Bacteriophage Penetration (0-2 hours):** Viral particles infiltrate biofilm matrix through size-selective diffusion, targeting specific pathogenic bacteria and creating localized clearance zones through bacterial lysis.
- **Enzymatic Matrix Degradation (2-6 hours):** Specialized enzymes (DNases, proteases, glycosidases) systematically break down EPS components, widening clearance zones and creating accessible pathways.

- ***Lactobacillus* Colonization (6-24 hours):** Beneficial bacteria actively migrate into cleared spaces, establishing protective microcolonies that produce antimicrobial compounds and compete for resources.

(C) Therapeutic Outcome (24+ hours): Illustrates successful biofilm disruption, characterized by key features including a fragmented pathogenic biofilm architecture, established *Lactobacillus* microcolonies that provide sustained protection, restored host tissue access for immune surveillance, and prevention of pathogenic recolonization through competitive exclusion.

Temporal Integration: The figure emphasizes that therapeutic success depends on precise timing and coordination between modalities. Early bacteriophage action creates opportunities for enzymatic penetration, which in turn facilitates the establishment of beneficial bacteria. This sequential approach addresses the multi-layered resistance mechanisms that make biofilm infections so recalcitrant to single-agent therapies.

Bacteriophage therapy can systematically disrupt biofilm structure through targeted bacterial lysis, creating clearance zones within biofilm architecture. Subsequently, matrix-degrading enzymes expand these cleared areas by breaking down structural components, while *Lactobacillus* bacteria colonize newly accessible spaces to prevent pathogenic reestablishment.

This temporal coordination leverages the unique strengths of each therapeutic modality while compensating for individual weaknesses. The result is a comprehensive treatment approach that addresses the complexity of biofilms through multiple simultaneous mechanisms. Early results suggest these combination strategies may finally overcome the therapeutic resistance that has made biofilm infections so challenging to treat [19].

Engineering solutions are transforming the *Lactobacillus* therapeutics landscape through four key innovations: smart encapsulation systems that provide targeted protection, biofilm-based delivery that harnesses natural community advantages, CRISPR-enhanced strains with optimized properties, and synergistic combination therapies that coordinate multiple mechanisms. These advances are moving the field from laboratory curiosity toward clinical reality.

6. REGULATORY FRAMEWORK: NAVIGATING LIVE BIOTHERAPEUTIC PRODUCT REQUIREMENTS

The regulatory landscape for Live Biotherapeutic Products presents unique challenges that significantly exceed those for traditional pharmaceuticals. Unlike chemical drugs with well-defined structures and predictable properties, living treatments must meet pharmaceutical standards for safety, effectiveness, and quality while accounting for inherent biological complexity and variability.

Comprehensive Characterisation Requirements: Characterization demands surpass those for conventional drugs, requiring comprehensive genomic analysis, detailed phenotypic profiling, and extensive stability testing that account for the dynamic nature of living systems. Manufacturers must demonstrate not only immediate safety and efficacy but also long-term genetic stability and absence of horizontal gene transfer potential [20].

Clinical Development Complexity: Clinical development presents additional challenges where traditional dose-response relationships may not apply to living therapeutics. Treatment success depends on intricate interactions among therapeutic bacteria, the patient's microbiome, the immune system, and infection characteristics. This complexity makes endpoint selection correspondingly difficult and requires innovative trial designs that account for inter-patient variability.

Manufacturing Quality Controls: Manufacturing controls must address biological variability while maintaining consistent therapeutic performance. This necessitates quality control methods specifically designed for living systems, including real-time monitoring of bacterial viability, genetic integrity, and functional activity throughout the production process. These requirements, while ensuring patient safety, significantly increase development costs and timelines compared to traditional pharmaceutical development. The regulatory pathway for *Lactobacillus* therapeutics requires navigating unprecedented complexity in characterization, manufacturing, and clinical development. While these requirements ensure safety and efficacy, they also create significant barriers to market entry that must be addressed through innovative regulatory science and collaboration between industry and agencies.

7. FUTURE PERSPECTIVES AND CLINICAL TRANSLATION

Lactobacillus anti-biofilm therapeutics stand at a pivotal crossroads, balancing demonstrated laboratory potential with limited clinical implementation. Several interconnected research priorities will determine whether these promising treatments can successfully transition to widespread clinical use.

Technological Innovation: Next-generation encapsulation systems, precision genetic engineering technologies, and sophisticated combination treatment protocols show exceptional promise for overcoming current formulation and delivery limitations. Smart materials that respond selectively to disease-specific environmental triggers could revolutionize targeted bacterial delivery, enabling treatments that activate precisely when and where needed.

Personalized Medicine Development: Understanding individual variation in therapeutic response through comprehensive analysis of patient genetics, microbiome composition, and disease characteristics will enable the development of sophisticated patient stratification strategies. Advanced biomarker development could facilitate real-time monitoring of therapeutic establishment and treatment effectiveness.

Manufacturing Innovation: Developing improved process control methodologies, enhanced bacterial stabilization techniques, and cost-effective scale-up approaches will significantly impact commercial viability and patient accessibility. Quality control methods specifically designed for living therapeutics require continued development to meet stringent regulatory standards while maintaining economic feasibility.

Regulatory Science Evolution: Establishing clearer regulatory guidelines, standardized testing protocols, and adaptive regulatory frameworks will reduce development uncertainties while maintaining appropriate safety standards. Innovative clinical trial designs that account for the unique properties of living therapeutics could significantly accelerate approval pathways.

The success of *Lactobacillus*-based anti-biofilm therapeutics depends on sustained and coordinated collaboration among academic researchers, biotechnology companies, regulatory agencies, and healthcare providers. This multidisciplinary approach, combined with continued innovation in supporting technologies, positions the field to make substantial contributions to clinical management of biofilm-associated infections in our current era of widespread antibiotic resistance.

8. CONCLUSIONS

Lactobacillus bacteria represent a paradigm shift in anti-biofilm therapeutic strategies, offering sophisticated multi-mechanistic approaches that directly address the complex nature of biofilm resistance. While current formulation and delivery challenges limit clinical translation, emerging technological solutions offer clear and achievable pathways to overcome these obstacles. Success requires carefully integrated approaches combining advanced formulation science, precision genetic engineering, and innovative delivery systems within appropriate regulatory frameworks. The convergence of these technological advances, coupled with growing clinical need and regulatory support, positions *Lactobacillus*-based therapeutics to make transformative contributions to clinical management of biofilm-associated infections. As traditional antibiotics increasingly fail against resistant pathogens, these living therapeutics offer renewed hope for patients suffering from persistent biofilm infections. The journey from laboratory bench to patient bedside remains challenging, but the potential rewards—for individual patients and global health—justify the continued investment and innovation required for success.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors declare no conflicts of interest related to this work. No financial or non-financial benefits have been received, nor are expected from any party directly or indirectly associated with the subject of this article.

Ethics Approval and Consent to Participate: Not applicable. This review article does not involve human participants, animal experimentation, or clinical trials.

Acknowledgements: We sincerely thank our institutional libraries for granting access to scientific databases and literature, which greatly supported the development of this review.

REFERENCES

[1] Mgomi FC, Yang YR, Cheng G, Yang ZQ. Lactic acid bacteria biofilms and their antimicrobial potential against pathogenic microorganisms. Biofilm. 2023;5:100118. doi: 10.1016/j.bioflm.2023.100118. PMID: 37125395; PMCID: PMC10139968.

[2] Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol. 2002;292(2):107-13. doi: 10.1078/1438-4221-00196. PMID: 12195733.

[3] Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276-301. doi: 10.1093/femsre/fux010. PMID: 28369412.

[4] Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322-32. doi: 10.1016/j.ijantimicag.2009.12.011. PMID: 20149602.

[5] Anjana, Tiwari SK. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front Cell Infect Microbiol. 2022;12:851140. doi: 10.3389/fcimb.2022.851140. PMID: 35651753; PMCID: PMC9149203.

[6] Umu ÖC, Bäuerl C, Oostindjer M, Pope PB, Hernández PE, Pérez-Martínez G, Diep DB. The potential of class II bacteriocins to modify gut microbiota to improve host health. PLoS One. 2016;11(10):e0164036. doi: 10.1371/journal.pone.0164036. PMID: 27695121; PMCID: PMC5047468.

[7] Duarte AC, Almeida SF, Coimbra J, Lecerf M, Ressier L, Freitas R, Bento L. Use of potential probiotic lactic acid bacteria (LAB) biofilms for the control of Listeria monocytogenes, Salmonella Typhimurium, and Escherichia coli biofilms formation. Front Microbiol. 2016;7:863. doi: 10.3389/fmicb.2016.00863. PMID: 27375580; PMCID: PMC4894990.

[8] Tahmourespour A, Salehi R, Kermanshahi RK, Eslami G. The anti-biofouling effect of *Lactobacillus* fermentum-derived biosurfactant against Streptococcus mutans. Biofouling. 2011;27(4):385-398. doi: 10.1080/08927014.2011.57 5458. PMID: 21534041.

[9] Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61(2):160-174. doi: 10.1159/000342079. PMID: 23037511.

[10] Liu H, Cui SW, Chen M, Li Y, Liang R, Xu F, Zhong F. Protective approaches and mechanisms of microencapsulation to the survival of probiotic bacteria during processing, storage and gastrointestinal digestion: a review. Crit Rev Food Sci Nutr. 2019;59(17):2863-2878. doi: 10.1080/10408398.2017.1377684. PMID: 28933562.

[11] Binda S, Hill C, Johansen E, Obis D, Pot B, Sanders ME, Tremblay A, Ouwehand AC. Criteria to qualify microorganisms as "probiotic" in foods and dietary supplements. Front Microbiol. 2020;11:1662. doi: 10.3389/fmicb.2020.01662. PMID: 32760367; PMCID: PMC7371409.

[12] Fenster K, Freeburg B, Hollard C, Wong C, Rønhave Laursen R, Ouwehand AC. The production and delivery of probiotics: a review of a practical approach. Microorganisms. 2019;7(3):83. doi: 10.3390/microorganisms7030083. PMID: 30893738; PMCID: PMC6463098.

[13] Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Groeger D, Van Pijkeren JP, Reid G. Live biotherapeutic products, a road map for safety assessment. Front Med (Lausanne). 2020;7:237. doi: 10.3389/fmed.2020.00237. PMID: 32671077; PMCID: PMC7319051.

[14] Pot B, Vandenplas Y. Factors that influence clinical efficacy of live biotherapeutic products. Eur J Med Res. 2021;26(1):40. doi: 10.1186/s40001-021-00509-7. PMID: 33849599; PMCID: PMC8042840.

[15] Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, Kotler E, Zur M, Regev-Lehavi D, Brik RB, Federici S, Horn M, Cohen Y, Moor AE, Zeevi D, Korem T, Kotler E, Harmelin A, Itzkovitz S, Maharshak N, Shibolet O, Pevsner-Fischer M, Shapiro H, Sharon I, Halpern Z, Segal E, Elinav E. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388-1405.e21. doi: 10.1016/j.cell.2018.08.041. PMID: 30193112.

[16] Cook MT, Tzortzis G, Charalampopoulos D, Khutoryanskiy VV. Microencapsulation of probiotics for gastrointestinal delivery. J Control Release. 2012;162(1):56-67. doi: 10.1016/j.jconrel.2012.06.003. PMID: 22698940.

[17] Liu L, Liu L, Guo S, Tang C, Zhou Y, Zhang J, Zhang Y. Biofilm-based delivery approaches and specific enrichment strategies of probiotics in the human gut. Gut Microbes. 2022;14(1):2126274. doi: 10.1080/19490976.2022.2126274. PMID: 36227838; PMCID: PMC9578482.

[18] Hidalgo-Cantabrana C, O'Flaherty S, Barrangou R. CRISPR-based engineering of next-generation lactic acid bacteria. Curr Opin Microbiol. 2017;37:79-87. doi: 10.1016/j.mib.2017.05.015. PMID: 28618305.

[19] Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumarasamy M, Norris JS, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Proehl F, Krummenacher C, Schriefer I, Burrowes B, Torres C, Large K, Dalai SC, Alaswad Z, Kebriaei R, Burgess LD, Kaushik A, Chen L, Kreiswirth BN, Chauhan A, Leung SS, Nazarian EJ, Townsend ML, Ostrowsky BE, Tomas M, Nigo M, Aslam S, Kaye KS, Patel R, Kaye KS. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954-17. doi: 10.1128/AAC.00954-17. PMID: 28807909; PMCID: PMC5610519.

[20] Ahmad MF, Aman F, Arif MS, Ahmad FA. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020;52(9):1397-1406. doi: 10.1038/s12276-020-0437-6. PMID: 32908212; PMCID: PMC8080583.